Olmesartan Medoxomil E Idroclorotiazide Alter (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil/hydrochlorothiazide is indicated for conditions affecting the cardiovascular system, primarily hypertension. It helps lower elevated blood pressure and reduce associated cardiovascular risk.

• Hypertension: Lowers systolic and diastolic blood pressure, helping to prevent stroke and heart attack.
• Hypertension with fluid retention: Combines ARB‑mediated vasodilation with diuretic‑induced fluid loss to improve blood pressure control.
• High‑risk cardiovascular patients: Contributes to overall risk reduction when used as part of a comprehensive antihypertensive regimen.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone‑driven sodium retention. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit NaCl reabsorption, increasing urinary sodium and water excretion. Together, they reduce peripheral resistance and plasma volume, producing an additive antihypertensive effect.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema involving face, lips or airway
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: Assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: Monitor serum potassium and sodium, especially when combined with other diuretics.
• Pregnancy: Avoid use; potential risk to fetus.
• Concomitant drugs: Review for interactions that affect potassium or renal function.
• Elderly patients: Start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: Keep below 25°C, in original packaging, protected from moisture.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid)

• Aliskiren combined with concurrent ACE inhibitor or ARB therapy.
• Potassium‑rich supplements or potassium‑sparing diuretics leading to hyperkalemia.
• NSAIDs that may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: May increase serum lithium levels.
• Antidiabetic agents: May require dose adjustment due to enhanced glucose lowering.
• Other antihypertensives: May cause additive blood pressure reduction.
• Corticosteroids: May potentiate electrolyte disturbances.
• Antimicrobials such as trimethoprim‑sulfamethoxazole affecting potassium balance.